A randomized, placebo‐controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)
Pharmacology, Toxicology and Pharmaceutical Science
2
3%
Agricultural and Biological Sciences
2
3%
Other
4
6%
Unknown
30
45%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 October 2024.
All research outputs
#3,781,313
of 31,712,529 outputs
Outputs from Clinical & Experimental Allergy
#740
of 4,844 outputs
Outputs of similar age
#74,338
of 451,497 outputs
Outputs of similar age from Clinical & Experimental Allergy
#8
of 40 outputs
Altmetric has tracked 31,712,529 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,844 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.1. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,497 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.